Abstract
A retrospective chart review of patients in British Columbia with multiple sclerosis prescribed beta-interferon (IFNbeta) between 1995 and 2001 was carried out to investigate reasons for the interruption of therapy. The highest proportion of interruptions (76/281; 27%) occurred in the first 6 months. The single most common reason was perceived lack of efficacy, cited by 84 of 281 (30%). Gender, disability, and disease duration were identified as factors influencing interruption of IFNbeta therapy.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adjuvants, Immunologic / administration & dosage
-
Adjuvants, Immunologic / adverse effects
-
Adjuvants, Immunologic / therapeutic use*
-
Adolescent
-
Adult
-
Chemical and Drug Induced Liver Injury / etiology
-
Culture
-
Drug Administration Schedule
-
Drug Utilization
-
Female
-
Glatiramer Acetate
-
Humans
-
Injections, Intramuscular
-
Injections, Subcutaneous
-
Interferon beta-1a
-
Interferon beta-1b
-
Interferon-beta / administration & dosage
-
Interferon-beta / adverse effects
-
Interferon-beta / therapeutic use*
-
Male
-
Middle Aged
-
Multiple Sclerosis / drug therapy*
-
Peptides / administration & dosage
-
Peptides / therapeutic use
-
Retrospective Studies
-
Treatment Failure
Substances
-
Adjuvants, Immunologic
-
Peptides
-
Interferon beta-1b
-
Glatiramer Acetate
-
Interferon-beta
-
Interferon beta-1a